Dr. Wilcox is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2165 N Decatur Rd
Decatur, GA 30033Phone+1 404-778-8500Fax+1 404-778-8562
Education & Training
- Intercampus Medical Genetics Training ProgramN/A, 1991 - 1994
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1989 - 1991
- Molecular Biology, UCLAPh.D, 1989 - 1989
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Pediatrics, 1988 - 1989
- David Geffen School of Medicine at UCLAClass of 1988
- Biochemistry and Mathematics, UCLABS, 1982 - 1982
Certifications & Licensure
- CA State Medical License 1989 - 2025
- GA State Medical License 2013 - 2025
- MS State Medical License 1969 - 2017
- American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
- American Board of Medical Genetics and Genomics Clinical Molecular Genetics and Genomics
Awards, Honors, & Recognition
- John M. Adams award for excellence in Pediatrics 1988
- UCLA Alumni Scholar, 1977-1982 1982
- Phi Beta Kappa 1982
- Join now to see all
Clinical Trials
- Fabry Disease Registry & Pregnancy Sub-registry Start of enrollment: 2001 Jul 31
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Start of enrollment: 2018 Sep 27
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease Start of enrollment: 2020 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsGlobal reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to ...Christoph Wanner, Alberto Ortiz, William R Wilcox, Robert J Hopkin, Jack Johnson
Molecular Genetics and Metabolism. 2023-07-01 - 15 citationsVenglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 stud...Patrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, Robert J Hopkin, Elena Lukina
Molecular Genetics and Metabolism. 2023-02-01 - 8 citationsClinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.Robert J Hopkin, Gustavo H Cabrera, John L Jefferies, Meng Yang, Elvira Ponce
Molecular Genetics and Metabolism. 2023-02-01
Journal Articles
- Hydrophobic moments and protein structure.Eisenberg, D., Weiss, R.M., Terwilliger, T.C., and Wilcox, W., Faraday Symp. Chem. Soc. 17:109 120
- The design, synthesis, and crystallization of an alpha helical peptide. Proteins: Structure, Function, and Genetics.Eisenberg, D., Wilcox, W., Eshita, S.M., Pryciak, P.M., Ho, S.P., and DeGrado, W.F, 1:16 22
- Hydrophobicity and amphiphilicity in protein structure.Eisenberg, D., Wilcox, W., and McLachlan, A.D, J. Cell. Biochem. 31:11 17
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The acrocallosal syndrome: report of 4 cases, review of the literature, and proposed diagnostic criteria.Wilcox, W.R. and Graham, J.M, Proc. Greenwood Genetic Center 12:56
- A N-terminal glycine to cysteine mutation in the collagen 1(I) chain produces an unusually severe phenotype.Wilcox, W., Scott, L., and Cohn, D, Am. J. Hum. Genet. 55:A367
- Histologic abnormalities in a case of infantile multifocal osteolysis.Krakow, D., Wilcox, W., Lachman, R.S., and Rimoin, D.L, Am. J. Hum. Genet. 55:A85
- Join now to see all
Lectures
- 10th Annual Asia Pacific LSD Symposium.Kuala Lumpur
- L.A. Office of the County Counsel.
- L.A. County Coroner’s Office.
- Join now to see all
Press Mentions
- Emory Advances Care for People with Rare DiseasesFebruary 24th, 2022
Grant Support
- Clinical Trial: A 12-Week Study To Evaluate The Safety Of At1001 In Patients WitNational Center For Research Resources2008
- A 12-Week Study To Evaluate The Safety Of At1001 In Patients With Fabry DiseaseNational Center For Research Resources2007
- Multi-Center, OPEN Label Study Of The Safety And Efficacy Of FabrazymeNational Center For Research Resources2006
- Multi-Center, OPEN Label Study Of The Safety And Efficacy Of Fabrazyme In PatienNational Center For Research Resources2005
- A Multicenter, OPEN Label Extension Study Agalactosidase A (R-Hagal)National Center For Research Resources2005
- A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study Of The SafetyNational Center For Research Resources2005
- Trial Of Antiresporptive Therapy For Osteopenia In Pediatric Gaucher PatientsNational Center For Research Resources2004
- Trial Of Antiresorptive Therapy For Osteopenia In Pediatric Gaucher PatientsNational Center For Research Resources2004
- Multicenter, OPEN Label Extension Study ...A-GalactosidNational Center For Research Resources2004
- Multi-Center, Randomized, Double-Blind, Placebo ControNational Center For Research Resources2004
- Effect Of FGFR3 Gene Mutation On Linear Bone GrowthNational Center For Research Resources1999–2001
- Safety &Efficacy Of Rhagal Replacement In Patients With Fabry'S DiseaseNational Center For Research Resources2000
- Collagen Stability In Osteogenesis ImperfectaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: